Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 26.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from Celgene Corporation, Eisai Inc., Genentech, and Novartis Pharmaceuticals Corporation.
OverviewThe optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medical interventions. The multidisciplinary Miami Breast Cancer Conference® has been bringing together surgical, medical, and radiation oncologists for 31 years, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging crossteam cooperation in the clinic. At the 31st Annual Miami Breast Cancer Conference®, pioneers of innovative approaches in each of these subspecialties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.
Target AudienceThis educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of Physicians’ Education Resource®, LLC (PER®) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with the ACCME Standards for Commercial Support™, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to the start of each activity. Participants are notified prior to the activity of the presence or absence of relevant financial relationships between faculty and commercial interests. Information disclosed includes the name of the faculty, nature of the relevant financial relationship (eg, member of speaker’s bureau, grant/research support, or consulting arrangement), and the name of the company/organization with which the relationship exists. Additionally, prior to the start of each activity, PER® discloses the source of commercial support to the participants.
Faculty, Staff, and Planner DisclosuresThe following individuals have relevant financial relationships with commercial interests to disclose:
Kathy S. Albain, MD, FACP
Advisory Board: Genomic Health
Kimberly Blackwell, MD
Grant/Research Support: Institute receives funding from: Roche/Genentech, Novartis, and Pfizer
Consultant: Novartis, Sandoz, and Roche
Speaker’s Bureau: Genomic Health
Patrick I. Borgen, MD
Consultant: Genomic Health
Speaker’s Bureau: Genomic Health and Myriad Genetics
Kevin Hughes, MD, FACS
Speaker’s Bureau: Myriad Genetics
Stock/Shareholder: 5AM Solutions
Other: Software developer, Hughes Risk Apps
Lance A. Liotta, MD, PhD
Stock/Shareholder: Theranostics Health
Eleftherios Mamounas, MD, MPH, FACS
Consultant: Pfizer, Eisai, Genomic Health Inc, Celgene, and GE Healthcare
Speaker’s Bureau: Genomic Health Inc
Hyman B. Muss, MD
Grant/Research Support: Numerous trials at UNC, not a PI on any project; all support to UNC and no signatory authority over any UNC account
Joyce O’Shaughnessy, MD
Advisory Board: Genentech Inc.
Consultant: Arno Therapeutics Inc, Eisai Inc, Genentech, Inc, GlaxoSmithKline, Johnson & Johnson, sanofi-aventis US, Novartis Pharmaceuticals, Pfizer, Celgene Corporation, Corcept Therapeutics, and Med Fusion, LLC
Mark Robson, MD
Grant/Research Support: AbbVie and AstraZeneca
Consultant: AbbVie, AstraZeneca, BioMarin Pharmaceutical Inc, and Tesaro Inc
Leslie Schover, PhD
Grant/Research Support: NCI STTR grant supported research on Internet-based intervention, future commercialization possible
Other support: Laclede and Fidia donated vaginal moisturizer to research discussed in nonhormonal approach to prevent vaginal atrophy
Debu Tripathy, MD
Grant/Research Support: Genentech/Roche
Sunil Verma, MD, MSEd, FRCPC
Grant/ Research Support: sanofi-aventis and Roche
Consultant: Novartis, Eli Lilly, Amgen, Roche, AstraZeneca, and Eisai
The following individuals have no relevant financial relationships with commercial interests:
Judy C. Boughey, MD; Harold J. Burstein, MD, PhD; Grant W. Carlson, MD; J. Michael Dixon, MD, OBE; Christina Giuliano, MD; Jay R. Harris, MD; Henry Kuerer, MD, PhD, FACS; Donna-Marie Manasseh, MD; Ellen T. Matloff, MS, CGC; Daniel A. Osman, MD; Lawrence J. Schneiderman, MD; Melvin J. Silverstein, MD, FACS; Donald L. Weaver, MD; and Julia White, MD
The Staff of PER®: Susan Peck, PhD; Dru S. Dace, PhD; Emily Valko Lohrmann, Wendy Ashmen, and Ann C. Lichti, CCMEP
At the time of posting, disclosure information for the following individuals was not available:
R. Douglas Macmillan, MD, MB ChB, FRCS; and Judith A. Salerno, MD, MS. Disclosure information for these individuals will be provided prior to the start of the conference during the welcome and introductions.
Off-Label Disclosure and DisclaimerThis activity will contain discussions about off-label/unapproved uses of drugs including but not limited to enzalutamide, PI3K inhibitors, trastuzumab emtansine, pertuzumab, trastuzumab, lapatinib, temsirolimus, sunitinib, crizotinib, neratinib, sorafenib, imatinib, erlotinib, gefitinb, everolimus, platinum agents, iniparib, veliparib, BMN673, palbociclib, LEE011, dasatinib, entinostat, capecitabine, nab-paclitaxel, ixabepilone, eribulin, bisphosphonates, anastrozole, exemestane, letrozole, fulvestrant, RNA-based multigene testing, genomic grade index, 21-gene recurrence score, IVDMIA breast cancer recurrence assay, and PAM50 assay to treat patients with breast cancer.
For additional information about approved uses, including approved indications, contraindications, and warnings, participants are advised to consult prescribing information for all products discussed or consult the Physicians’ Desk Reference. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this CME activity.
January 27, 2017
New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies - New York
January 27, 2017
New York, NY
Jan 29, 2017
Jan 29, 2017
Jan 29, 2017
Jan 29, 2017